Literature DB >> 22826477

Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi.

Carmel B Stober1, Selma M B Jeronimo, Nubia N Pontes, E Nancy Miller, Jenefer M Blackwell.   

Abstract

Visceral leishmaniasis (VL) is fatal if untreated, and there are no vaccines for this disease. High levels of CD4-derived interferon-γ (IFN-γ) in the presence of low levels of interleukin-10 (IL-10) predicts vaccine success. Tumor necrosis factor-α (TNF-α) is also important in this process. We characterized human immune responses in three groups exposed to Leishmania infantum chagasi in Brazil: 1) drug-cured VL patients (recovered VL); 2) asymptomatic persons with positive Leishmania-specific delayed-type hypersensitivity skin reactions (DTH+); and 3) DTH-negative household contacts. Magnitude of DTH correlated with crude Leishmania antigen-driven IFN-γ, TNF-α, and IL-5, but not IL-10. DTH+ persons showed equivalent levels of IFN-γ, but higher levels of IL-10, to tryparedoxin peroxidase and Leishmania homolog of receptor for activated C kinase compared with recovered VL patients. The IFN-γ:IL-10 and TNF-α:IL-10 ratios were higher in recovered VL patients than in DTH+ persons. Seven of 11 novel candidates (R71, L37, N52, L302.06, M18, J41, and M22) elicited cytokine responses (36-71% of responders) in recovered VL patients and DTH+ persons. This result confirmed their putative status as cross-species vaccine/immunotherapeutic candidates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22826477      PMCID: PMC3516316          DOI: 10.4269/ajtmh.2012.12-0180

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  38 in total

1.  Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up.

Authors:  S M Jeronimo; M J Teixeira; A d Sousa; P Thielking; R D Pearson; T G Evans
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

2.  Expression cloning of a protective Leishmania antigen.

Authors:  E Mougneau; F Altare; A E Wakil; S Zheng; T Coppola; Z E Wang; R Waldmann; R M Locksley; N Glaichenhaus
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

3.  A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis.

Authors:  Jaya Chakravarty; Subodh Kumar; Sonali Trivedi; Vijay K Rai; Anup Singh; Jill A Ashman; Elsa M Laughlin; Rhea N Coler; Stuart J Kahn; Anna Marie Beckmann; Karen D Cowgill; Steven G Reed; Shyam Sundar; Franco M Piazza
Journal:  Vaccine       Date:  2011-03-15       Impact factor: 3.641

4.  Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection.

Authors:  Ivonise Follador; Cibele Araújo; Olívia Bacellar; Clarissa B Araújo; Lucas P Carvalho; Roque P Almeida; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2002-05-07       Impact factor: 9.079

5.  Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice.

Authors:  Carmel B Stober; Uta G Lange; Mark T M Roberts; Antonio Alcami; Jenefer M Blackwell
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

6.  From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection.

Authors:  Carmel B Stober; Uta G Lange; Mark T M Roberts; Brian Gilmartin; Richard Francis; Renata Almeida; Christopher S Peacock; Sharon McCann; Jenefer M Blackwell
Journal:  Vaccine       Date:  2005-12-20       Impact factor: 3.641

Review 7.  Leishmaniasis vaccines: past, present and future.

Authors:  Farrokh Modabber
Journal:  Int J Antimicrob Agents       Date:  2010-08-30       Impact factor: 5.283

8.  An analysis of T cell responsiveness in Indian kala-azar.

Authors:  D L Sacks; S L Lal; S N Shrivastava; J Blackwell; F A Neva
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

9.  Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan.

Authors:  Selma M B Jeronimo; Priya Duggal; Nicholas A Ettinger; Eliana T Nascimento; Gloria R Monteiro; Angela P Cabral; Nubia N Pontes; Henio G Lacerda; Paula V Queiroz; Carlos E M Gomes; Richard D Pearson; Jenefer M Blackwell; Terri H Beaty; Mary E Wilson
Journal:  J Infect Dis       Date:  2007-09-13       Impact factor: 5.226

10.  Cutaneous leishmaniasis: The prospects for a killed vaccine.

Authors:  C L Greenblatt
Journal:  Parasitol Today       Date:  1988-02
View more
  10 in total

1.  Evaluation of In vitro and In vivo Protective Efficacy of Bauhinia variegata Against Leishmania donovani in Murine Model.

Authors:  Gurpreet Kaur; Kalpana Chauhan; Namrata Anand; Sukhbir Kaur
Journal:  Acta Parasitol       Date:  2021-02-02       Impact factor: 1.440

2.  Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.

Authors:  Micheli Luize Barbosa Santos; Dirlei Nico; Fabrícia Alvisi de Oliveira; Aline Silva Barreto; Iam Palatnik-de-Sousa; Eugenia Carrillo; Javier Moreno; Paula Mello de Luca; Alexandre Morrot; Daniela Santoro Rosa; Marcos Palatnik; Cristiane Bani-Corrêa; Roque Pacheco de Almeida; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2017-03-07       Impact factor: 7.561

3.  Leishmania major large RAB GTPase is highly immunogenic in individuals immune to cutaneous and visceral leishmaniasis.

Authors:  Rym Chamakh-Ayari; Mehdi Chenik; Ahmed Sahbi Chakroun; Narges Bahi-Jaber; Karim Aoun; Amel Meddeb-Garnaoui
Journal:  Parasit Vectors       Date:  2017-04-17       Impact factor: 3.876

4.  Leishmania infantum (syn. L. chagasi) parasites affect the release of soluble CD14 by infected macrophages.

Authors:  Michelle Barreto Gomes Melo; Luana Celina Seraphim Cunha; Cárcia Santana Passos Barreto; Fabrícia Alvisi de Oliveira Mendonça; Micheli Luize Barbosa Santos; Danielle Sacramento; Amélia Ribeiro de Jesus; Roque Pacheco Almeida; Priscila Lima Dos Santos
Journal:  Parasitol Res       Date:  2021-08-05       Impact factor: 2.289

5.  Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis.

Authors:  Om Prakash Singh; Carmel B Stober; Abhishek Kr Singh; Jenefer M Blackwell; Shyam Sundar
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25

6.  Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors.

Authors:  Dirlei Nico; Daniel Ferreira Feijó; Naiara Maran; Alexandre Morrot; Julio Scharfstein; Marcos Palatnik; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Parasit Vectors       Date:  2012-11-14       Impact factor: 3.876

Review 7.  A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?

Authors:  Johan van Griensven; Ermias Diro; Rogelio Lopez-Velez; Koert Ritmeijer; Marleen Boelaert; Ed E Zijlstra; Asrat Hailu; Lutgarde Lynen
Journal:  PLoS Negl Trop Dis       Date:  2014-08-07

8.  Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.

Authors:  Dirlei Nico; Daniele Crespo Gomes; Iam Palatnik-de-Sousa; Alexandre Morrot; Marcos Palatnik; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2014-06-11       Impact factor: 7.561

9.  NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.

Authors:  Dirlei Nico; Fernanda Martins Almeida; Juliana Maria Motta; Fellipe Soares Dos Santos Cardoso; Celio Geraldo Freire-de-Lima; Leonardo Freire-de-Lima; Paula Melo de Luca; Ana Maria Blanco Martinez; Alexandre Morrot; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

10.  Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters.

Authors:  Laura Fernández; Eugenia Carrillo; Lucas Sánchez-Sampedro; Carmen Sánchez; Ana Victoria Ibarra-Meneses; M Angeles Jimenez; Valter Dos Anjos Almeida; Mariano Esteban; Javier Moreno
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.